PLG and Alzheimer disease: The use of human NSCs for intranasal transplantation in the treatment of AD has the greatest potential as a non-invasive treatment option that reduces Aβ levels in animal models of AD by inhibiting the activity of cathepsin B, plasmin, and insulin-degrading enzymes [79].